September industry news: investigational gene therapy demonstrates motor function improvement in patients with Parkinson’s

Written by Sharon Salt, Senior Editor

This month our industry news round-up includes announcements on an investigational gene therapy for advanced Parkinson’s disease, an inhaled drug for acute migraine, Libervant™ (diazepam) Buccal Film for seizure clusters, new MAVENCLAD® (cladribine tablets) data for relapsing multiple sclerosis, ATA188 data for progressive multiple sclerosis and satralizumab in neuromyelitis optica spectrum disorder. Take a look a September’s headlines below: Investigational gene therapy demonstrates motor function improvement in patients with Parkinson’s Inhaled drug for acute migraine fails Phase III clinical trial US FDA rejects oral diazepam-based drug for management of seizure clusters New MAVENCLAD® data highlights rapid onset of action for...

To view this content, please register now for access

It's completely free